| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Richard J L Anney, Craig A Olsson, Mehrnoush Lotfi-Miri, George C Patton, Robert Williamso. Nicotine dependence in a prospective population-based study of adolescents: the protective role of a functional tyrosine hydroxylase polymorphism. Pharmacogenetics. vol 14. issue 2. 2004-09-30. PMID:15077008. |
dopamine is a key neurotransmitter of the mesolimbic reward pathway in the human brain, and tyrosine hydroxylase (th) is the rate-limiting enzyme in dopamine biosynthesis. |
2004-09-30 |
2023-08-12 |
human |
| David B Ry. Parkinson's disease and RLS: the dopaminergic bridge. Sleep medicine. vol 5. issue 3. 2004-09-28. PMID:15165542. |
dopamine is a neurotransmitter that modulates diverse waking behaviors including movement, motivation, cognition, reward, and feeding. |
2004-09-28 |
2023-08-12 |
Not clear |
| Anna E Goudriaan, Jaap Oosterlaan, Edwin de Beurs, Wim Van den Brin. Pathological gambling: a comprehensive review of biobehavioral findings. Neuroscience and biobehavioral reviews. vol 28. issue 2. 2004-08-06. PMID:15172761. |
results from the pg studies fit in with recent theoretical models of addiction and pg, which stress the involvement of brain reward pathways, neurotransmitter abnormalities, the frontal cortex and the psychophysiological stress system. |
2004-08-06 |
2023-08-12 |
Not clear |
| Jean-Martin Beaulieu, Tatyana D Sotnikova, Wei-Dong Yao, Lisa Kockeritz, James R Woodgett, Raul R Gainetdinov, Marc G Caro. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the National Academy of Sciences of the United States of America. vol 101. issue 14. 2004-06-10. PMID:15044694. |
dopamine (da) is a neurotransmitter involved in the control of locomotion, emotion, cognition, and reward. |
2004-06-10 |
2023-08-12 |
mouse |
| George R Uh. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Movement disorders : official journal of the Movement Disorder Society. vol 18 Suppl 7. 2004-03-29. PMID:14531049. |
we review the basic science of the dopamine transporter (dat), a key neurotransmitter for locomotor control and reward systems, including those lost or deranged in parkinson's disease (pd). |
2004-03-29 |
2023-08-12 |
human |
| John F Cryan, Fabrizio Gasparini, Gino van Heeke, Athina Marko. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug discovery today. vol 8. issue 22. 2004-02-10. PMID:14690633. |
these strategies focus on altering reward processes in the brain by modulating various neurotransmitter systems: the most promising include dopamine d(3) receptor antagonists, noradrenaline reuptake inhibitors, gaba(b) receptor agonists, metabotropic glutamate 5 (mglur5) receptor antagonists, cannabinoid cb1 receptor antagonists, and corticotropin releasing factor (crf) 1 receptor antagonists. |
2004-02-10 |
2023-08-12 |
Not clear |
| Ann S Clark, Leslie P Henderso. Behavioral and physiological responses to anabolic-androgenic steroids. Neuroscience and biobehavioral reviews. vol 27. issue 5. 2003-11-26. PMID:14505684. |
in particular, we have focused on studies in rodents that have examined how aas alter aggression, sexual behaviors, anxiety, reward, learning, and locomotion and how aas alter the expression and function of neurotransmitter systems and other signaling molecules that underlie these behaviors. |
2003-11-26 |
2023-08-12 |
human |
| Richard Nass, Randy D Blakel. The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Annual review of pharmacology and toxicology. vol 43. 2003-09-09. PMID:12415122. |
the neurotransmitter dopamine (da) plays a central role in the coordination of movement, attention, and the recognition of reward. |
2003-09-09 |
2023-08-12 |
caenorhabditis_elegans |
| Charles A Dackis, Kevin G Lynch, Elmer Yu, Frederick F Samaha, Kyle M Kampman, James W Cornish, Amy Rowan, Sabrina Poole, Lenae White, Charles P O'Brie. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug and alcohol dependence. vol 70. issue 1. 2003-09-03. PMID:12681523. |
in addition, the neurotransmitter actions of modafinil are opposite to cocaine-induced neuroadaptations affecting dopamine and glutamate reward circuits. |
2003-09-03 |
2023-08-12 |
human |
| Nurulain Zaver. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life sciences. vol 73. issue 6. 2003-07-17. PMID:12801588. |
these discoveries have facilitated the understanding of the role of the orl1-n/ofq system in a variety of processes such as pain modulation, anxiety, food intake, learning, memory, neurotransmitter release, reward pathways, and tolerance development. |
2003-07-17 |
2023-08-12 |
human |
| Jong Y Bahk, Shupeng Li, Moon S Park, Myeong O Ki. Dopamine D1 and D2 receptor mRNA up-regulation in the caudate-putamen and nucleus accumbens of rat brains by smoking. Progress in neuro-psychopharmacology & biological psychiatry. vol 26. issue 6. 2003-03-26. PMID:12452531. |
the neurotransmitter dopamine (da) is important in the reward and reinforcing properties of many addictive drugs: however, the effect of nicotine by cigarette smoking itself on the expression of da receptors in the caudate-putamen (cpu), nucleus accumbens (nac) and olfactory tubercle (otu) has not been elucidated completely. |
2003-03-26 |
2023-08-12 |
rat |
| P N Deslandes, D M Pache, R D E Sewel. Drug dependence: neuropharmacology and management. The Journal of pharmacy and pharmacology. vol 54. issue 7. 2003-01-23. PMID:12162706. |
work conducted in this field has shown that stimulants and opioids, despite interactions with different receptor types and different neurotransmitter reuptake transporters, appear to share a common action on brain reward pathways. |
2003-01-23 |
2023-08-12 |
Not clear |
| J Vetulan. Drug addiction. Part II. Neurobiology of addiction. Polish journal of pharmacology. vol 53. issue 4. 2002-07-19. PMID:11990077. |
the main neurotransmitter involved in the reward is dopamine, but other monoamines and acetylcholine may also participate. |
2002-07-19 |
2023-08-12 |
Not clear |
| Nora D Volkow, Gene-Jack Wang, Joanna S Fowler, Jean Logan, Millard Jayne, Dinko Franceschi, Cristopher Wong, Samuel J Gatley, Andrew N Gifford, Yu-Shin Ding, Naomi Pappa. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse (New York, N.Y.). vol 44. issue 3. 2002-06-20. PMID:11954049. |
dopamine, a neurotransmitter involved with motivation and reward, its believed to regulate food intake in laboratory animals by modulating its rewarding effects through the nucleus accumbens (na). |
2002-06-20 |
2023-08-12 |
human |
| K Blum, E R Braverman, J M Holder, J F Lubar, V J Monastra, D Miller, J O Lubar, T J Chen, D E Coming. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. Journal of psychoactive drugs. vol 32 Suppl. 2001-04-26. PMID:11280926. |
the net effect of neurotransmitter interaction at the mesolimbic brain region induces "reward" when dopamine (da) is released from the neuron at the nucleus accumbens and interacts with a dopamine d2 receptor. |
2001-04-26 |
2023-08-12 |
Not clear |
| N D Volkow, G Wang, J S Fowler, J Logan, M Gerasimov, L Maynard, Y Ding, S J Gatley, A Gifford, D Francesch. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 21. issue 2. 2001-04-05. PMID:11160455. |
alternatively methylphenidate-induced increases in da, a neurotransmitter involved with motivation and reward, could enhance the salience of the task facilitating the "interest that it elicits" and thus improving performance. |
2001-04-05 |
2023-08-12 |
human |
| S Dehaene, J P Changeu. Reward-dependent learning in neuronal networks for planning and decision making. Progress in brain research. vol 126. 2001-01-18. PMID:11105649. |
at the molecular level, the reward signal is postulated to be a neurotransmitter such as dopamine, which exerts a global modulatory action on prefrontal synaptic efficacies, either via volume transmission or via targeted synaptic triads. |
2001-01-18 |
2023-08-12 |
human |
| D E Comings, K Blu. Reward deficiency syndrome: genetic aspects of behavioral disorders. Progress in brain research. vol 126. 2001-01-18. PMID:11105655. |
since the primary neurotransmitter of the reward pathway is dopamine, genes for dopamine synthesis, degradation, receptors, and transporters are reasonable candidates. |
2001-01-18 |
2023-08-12 |
human |
| J N Oak, J Oldenhof, H H Van To. The dopamine D(4) receptor: one decade of research. European journal of pharmacology. vol 405. issue 1-3. 2001-01-08. PMID:11033337. |
dopamine is an important neurotransmitter involved in motor control, endocrine function, reward, cognition and emotion. |
2001-01-08 |
2023-08-12 |
mouse |
| T Li, Z H Zhu, X Liu, X Hu, J Zhao, P C Sham, D A Collie. Association analysis of polymorphisms in the DRD4 gene and heroin abuse in Chinese subjects. American journal of medical genetics. vol 96. issue 5. 2000-11-13. PMID:11054768. |
because the dopamine system is involved in reward, its neurotransmitter receptors are candidates for etiological involvement in addiction. |
2000-11-13 |
2023-08-12 |
human |